Canopy’s stock reversed on earnings after seeing a rally sparked by the possibility of marijuana reform in the U.S.

Canadian cannabis producer cuts debt load and shows revenue growth in key segments while pushing ahead with U.S. expansion.

Canopy Growth Q3 sales hit C$74.76 million, surpassing estimates. Medical cannabis revenue rose 16%, while adjusted EBITDA loss improved 61% year-over-year.

Aurora Cannabis (NASDAQ: ACB) surged 45% after reporting record earnings, boosting CGC, TLRY, and CRON stocks.

Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC) today announces its financial results ...

Luc Mongeau, the newly appointed CEO, emphasized his commitment to advancing Canopy Growth toward sustained profitability and positive cash generation. He highlighted strengths in the medical cannabis ...

Be cautious ahead of Canopy Growth Corporation's FQ3 results, as weak financials and low margins may hinder stock performance ...

Canopy Growth Corp. reported a loss of $121.9 million in its latest quarter compared with a loss of $216.8 million in the ...

From political maneuvering in Washington to major corporate developments across the global cannabis landscape, this week has ...

Canopy Growth is continuing its run from yesterday, currently trading at $4.0400, up 0.3900, gaining 10.6849% on the TSX on ...

Shares in Canopy Growth fell sharply Friday morning after the company's loss missed expectations in the fiscal third quarter. Shares fell over 18% to 3.27 Canadian dollars ($2.29).